Development of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry (HPLC-MS/MS) Method to Determine the Presence of Rivastigmine in Human Plasma in Clinical Studies of Comparative Pharmacokinetics
https://doi.org/10.37489/0235-2990-2022-67-11-12-22-28
Abstract
The basis for conducting bioequivalence studies is the determination of the bioavailability of the active substance of the drug at its place of action by establishing the concentration of the drug in biological fluids using sensitive analytical techniques. The bioanalytical technique used should provide reliable results which would lead to satisfactory level of interpretation. To investigate the bioequivalence of rivastigmine preparations, an 8 times more sensitive method (compared to the data in the available literature) for the quantitative determination of rivastigmine in human blood plasma by HPLC-MS/MS was developed. Rivastigmine is extracted from plasma by precipitation of plasma proteins with acetonitrile. Chromatographic separation of rivastigmine and the internal standard was carried out on a YMC Triart C18. 50×2.0 mm (1.9 µm) column in a gradient elution mode with a flow rate of 0.5 ml/min. A 0.1% solution of ammonium hydroxide and acetonitrile were used as mobile phases. The lower limit of the quantitative determination of the method was 25 pg/ml.
About the Authors
M. S. Dolov
Lomonosov Moscow State University; Analytical center «Exacte Labs»
Russian Federation
Competing Interests:
Russian Federation
Maksim S. Dolov.
1 Leninskie gory, Moscow, 119991
Scopus Author ID: 57210957022
Competing Interests:
None
L. A. Fishgoit
Lomonosov Moscow State University
Russian Federation
Competing Interests:
Russian Federation
Larisa A. Fishgoit — Ph. D. in chemistry, Associate Professor, Senior Researcher, Lomonosov Moscow State University.
Moscow
Scopus Author ID: 6506597447
Competing Interests:
None
P. D. Sobolev
Analytical center «Exacte Labs»
Russian Federation
Competing Interests:
Russian Federation
Pavel D. Sobolev.
Moscow.
Scopus Author ID: 57210957022
Competing Interests:
None
E. P. Tkach
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Elizaveta P. Tkach.
Moscow
Competing Interests:
None
References
1. Dranitsyna M.A., Zakharova T.V., Niyazov R.R. Svojstva protsedury dvukh odnostoronnikh testov dlya priznaniya bioekvivalentnosti lekarstvennykh preparatov. Remedium. Zhurnal o Rossijskom Rynke Lekarstv I Meditsinskoj Tekhniki. 2019; 3: 40–47. (in Russian)
2. Niyazov R.R., Rozhdestvenskij D.A., Vasil'ev A.N., Gavrishina E.V., Dranitsyna M.A., Kulichev D.A. Regulyatornye aspekty registratsii vosproizvedennykh i gibridnykh lekarstvennykh preparatov v Evrazijskom ekonomicheskom sojyuze. Remedium. Zhurnal o Rossijskom Rynke Lekarstv I Meditsinskoj Tekhniki. 2018; 7–8: 6–19. (in Russian)
3. Postanovlenie Pravitel'stva Rossijskoj Federatsii ot 29.12.2021 № 2544 «O vnesenii izmenenij v gosudarstvennujyu programmu Rossijskoj Federatsii «Razvitie farmatsevticheskoj i meditsinskoj promyshlennosti». (in Russian)
4. Rasporyazhenie Pravitel'stva RF ot 12.10.2019 N 2406-r «Ob utverzhdenii perechnya zhiznenno neobkhodimykh i vazhnejshikh lekarstvennykh preparatov na 2020 god». (in Russian)
5. Prikaz Ministerstva zdravookhraneniya Rossijskoj Federatsii ot 17 fevralya 2022 goda N 81n «Ob utverzhdenii standarta meditsinskoj pomoshchi patsientam pozhilogo i starcheskogo vozrasta pri kognitivnykh rasstrojstvakh (diagnostika i lechenie)». (in Russian)
6. Prikaz Ministerstva zdravookhraneniya Rossijskoj Federatsii ot 20 dekabrya 2012 g. № 1228n «Ob utverzhdenii standarta spetsializirovannoj meditsinskoj pomoshchi pri bolezni Al'tsgejmera».(in Russian)
7. Prikaz Ministerstva zdravookhraneniya Rossijskoj Federatsii ot 28 dekabrya 2012 g. № 1621n «Ob utverzhdenii standarta pervichnoj mediko-sanitarnoj pomoshchi pri organicheskikh, vkljyuchaya simptomaticheskie, psikhicheskikh rasstrojstvakh, dementsii pri drugikh boleznyakh, klassifitsirovannykh v drugikh rubrikakh».(in Russian)
8. Instruktsiya po meditsinskomu primenenijyu lekarstvennogo preparata Ekselon, kapsuly, Novartis Farma AG, Shvejtsariya. Gosudarstvennyj reestr lekarstvennykh sredstv Rossijskoj Federatsii. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=55f3d412-750a-4b52-ad33-fc2561306088 (data obrashcheniya 13 noyabrya 2022 g.). (in Russian)
9. Reshenie Soveta Evrazijskoj ekonomicheskoj komissii ot 3 noyabrya 2016 g. N 85 «Ob utverzhdenii Pravil provedeniya issledovanij bioekvivalentnosti lekarstvennykh preparatov v ramkakh Evrazijskogo ekonomicheskogo sojyuza». (in Russian)
10. Bhatt J., Subbaiah G., Kambli S. et al. A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci., 2007; 852 (1–2): 115–121. doi: 10.1016/j.jchromb.2007.01.003.
11. Amini H., Ahmadiani A. High-performance liquid chromatographic determination of rivastigmine in human plasma for application in pharmacokinetic studies. Iran J Pharm Res. 2010; 9 (2): 115–121.
12. Fiziko-khimicheskie svojstva rivastigmina: https://www.rlsnet.ru/active-substance/rivastigmin-2281 (data obrashcheniya 21.11.22). (in Russian)
13. Strukturnaya formula rivastigmina: https://pubchem.ncbi.nlm.nih.gov/compound/77991 (data obrashcheniya 22.11.22)
14. Strukturnaya formula atazanavira-d5: https://pub-chem.ncbi.nlm.nih.gov/compound/25241200#section=Other-Identifiers (data obrashcheniya 22.11.22)
15. Pommier F., Frigola R. Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003; 784 (2): 301–313. doi: 10.1016/s1570-0232(02)00816-4.
16. Frankfort S. V., Ouwehand M., van Maanen M. J., Rosing H., Tulner L. R., Beijnen J. H. A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry. Rapid Commun Mass Spectrom. 2006; 20 (22): 3330–3336. doi: 10.1002/rcm.2737.
17. Arumugam K., Chamallamudi M. R., Gilibili R. R. et al. Development and validation of a HPLC method for quantification of rivastigmine in rat urine and identification of a novel metabolite in urine by LC-MS/MS. Biomed Chromatogr. 2011 25 (3): 353-361. doi: 10.1002/bmc.1455.
18. Sato Y., Michihara A., Nagatsuka Y., Yamamoto K., Shirakawa M., Katayama H. High performance liquid chromatography coupled with mass spectrometry for simultaneous determination of rivastigmine and its metabolite in rat plasma. Acta Chromatographica. 2022; 34 (4): 437–443. doi: 10.1556/1326.2021.00989
Review
For citations:
Dolov M.S., Fishgoit L.A., Sobolev P.D., Tkach E.P. Development of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry (HPLC-MS/MS) Method to Determine the Presence of Rivastigmine in Human Plasma in Clinical Studies of Comparative Pharmacokinetics. Antibiot Khimioter = Antibiotics and Chemotherapy. 2022;67(11-12):22-28. (In Russ.) https://doi.org/10.37489/0235-2990-2022-67-11-12-22-28
Views:
447
Email this article 